Cartalax
A synthetic Ala-Glu-Asp tripeptide from the Khavinson bioregulator family studied for cartilage and connective-tissue gene regulation.
What Cartalax is
Cartalax is the synthetic tripeptide alanine-glutamic acid-aspartic acid (AED). It belongs to the ultrashort peptide bioregulator set associated with Vladimir Khavinson’s research program. Investigators study Cartalax for tissue-selective effects on cartilage, chondrocytes, and related connective-tissue cell models.
English-language peer-reviewed coverage is thinner than for major clinical peptides. Available work embeds AED among short peptides that can enter cells, interact with nuclear targets, and modulate gene expression linked to extracellular matrix maintenance and cellular aging phenotypes. Much primary detail still sits in Russian-institute literature and subsequent systematic reviews.
For SEO dosage pages, honesty matters: Cartalax does not have a large Western randomized-dose evidence base. Reported handling ranges below are research-community reference points and review-linked mechanistic context, not clinical prescribing standards. Research use only.
Cartalax has been studied in human trials, which is not true of most compounds in this library. The figures below come from that work.
How it works
As an ultrashort peptide, AED is investigated for carrier-mediated transport (POT/LAT family discussions appear in Khavinson-linked transport papers) and subsequent nuclear/epigenetic modulation rather than classical long-residence GPCR agonism. In cartilage-oriented models, research interest centers on chondrocyte gene programs, matrix protein expression, and senescence-associated markers. The precise target map is still an active research question.
Who works with it, and what they are measuring
Gerontology institutes, connective-tissue biology labs, and groups mapping ultrashort peptide transport and gene regulation are the core audience. Joint-health product marketers often outrun the peer-reviewed dose literature, so careful researchers separate mechanistic papers from commercial claims.
What the research examines
Each tag marks a field where this compound appears in research. Appearing in a literature is not the same as working.
How it appears in the literature
Amounts reported in published research, shown for reference. Not a protocol.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Research-supply and bioregulator protocol discussions (limited Western RCT anchoring) | 1 mg – 2 mg | cyclic research schedules (often described as courses rather than indefinite daily use) | subcutaneous or topical research formats |
| In vitro / cell-culture bioregulator work | 1 mcg – 100 mcg | media exposure per experimental design | in vitro |
Handling & storage
Lyophilized Cartalax is stored cold, dry, and light-protected. After reconstitution, refrigerate and use within the laboratory’s validated window; avoid freeze-thaw cycling of working solutions when possible.
Notes on combined research
In bioregulator literature Cartalax is sometimes discussed alongside other tissue-targeted short peptides (for example cartilage complex comparisons or fibroblast-oriented peptides) when researchers map organ-specific cytomedine sets. It may also appear near collagen-support or joint-matrix research tools. Evidence for formal synergistic stacks is limited.
Cartalax questions
There is no large, widely replicated Western dose-finding trial series. Research-community materials often mention about 1–2 mg per administration in cyclic protocols. Treat that as a thin secondary reference range, not a validated medical dose.
For a 20 mg lyophilized vial, 2 mL bacteriostatic water yields 1 mg per 0.1 mL, which simplifies 1–2 mg research measurements. Confirm against your label and pipette tolerances.
Secondary bioregulator write-ups sometimes describe daily administrations during short courses, then time off. Primary English dose-frequency standards are not well established.
Any chart should openly state the weak clinical dose literature and distinguish in vitro concentrations from in vivo research handling. Overconfident charts are a red flag for this compound.
Detailed human pharmacokinetic half-life data are sparse in major indexed sources. Ultrashort peptides generally clear quickly; durable claims usually refer to downstream gene-expression effects rather than long plasma residence.
Research discussions sometimes group it with other Khavinson-style bioregulators or matrix-support compounds. Formal controlled stack trials are limited, so combinations remain experimental research questions.
Both parenteral research handling and topical/connective-tissue research formats are discussed in secondary sources. Route should match the specific experimental design and material grade.
No. It is a three-amino-acid synthetic peptide studied for regulatory effects on cartilage-related cells, not a bulk collagen supplement.
Read the research yourself
Each citation was checked against PubMed before it went on this page. If we cannot link it, we do not claim it.